Q32 Bio Stock Surges on Positive Clinical Trial Results for Hair Loss Treatment
Shares of Q32 Bio (NASDAQ: QTTB) surged by over 90% after the company announced positive results from a Phase 2a clinical trial for its experimental hair loss treatment, bempikibart. The drug met its primary efficacy goal with patients showing an average reduction in scalp hair loss severity of 35%. However, shares later pulled back slightly due to news of a $200 million stock offering.
Tickers: $QTTB